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Abstract 
Pulmonary edema is a hallmark of acute lung injury (ALI), consisting of various degrees of 
water and proteins. Physiologically, sodium enters through apical sodium channels 
(ENaC) and is extruded basolaterally by a sodium-potassium-adenosine-triphosphatase 
pump (Na+/K+-ATPase). Water follows to maintain isoosmolar conditions and to keep 
alveoli dry. We postulated that the volatile anesthetic sevoflurane would positively impact 
edema resolution in an in vitro and in vivo model of ALI. 
Alveolar epithelial type II cells (AECII) and mixed alveolar epithelial cells (mAEC) were 
stimulated with 20 µg/ml lipopolysaccharides (LPS) and co-exposed to sevoflurane for 8 
hours. In vitro active sodium transport via ENaC and Na+/K+-ATPase was determined, 
assessing 22sodium and 86rubidium influx, respectively. Intratracheally applied LPS (150 
µg) was used for the in vivo ALI in rats under sevoflurane or propofol anesthesia (8 
hours). Oxygenation index (PaO2/FiO2) was calculated and lung edema was assessed 
determining lung wet/dry ratio. 
In AECII LPS decreased activity of ENaC and Na+/K+-ATPase, both by 17% and 16%, 
respectively (p<0.05). These effects were reversible in the presence of sevoflurane 
(p<0.05). Considerably better oxygenation was observed with an increase of PaO2/FiO2 
from 189 mmHg to 454 mmHg after 8 hours (p<0.05) in the sevoflurane/LPS compared to 
propofol/LPS group. Wet/dry-ratio in sevoflurane/LPS was reduced by 21.6% in 
comparison to propofol/LPS-treated animals (p<0.05). 
Sevoflurane has a stimulating effect on ENaC and Na+/K+-ATPase in vitro in LPS-injured 
AECII. In vivo experiments, however, give strong evidence that sevoflurane does not 
impact on water reabsorption and edema resolution, but possibly on edema formation.
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Introduction 
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are a major cause 
of acute respiratory failure in critically ill patients [1]. Mortality of ARDS remains high since 
its first description by Ashbaugh and colleagues [2], although lung protective ventilatory 
strategies have reduced mortality from 60-70% to 35-40% [3], [4]. While drug treatment is 
intensively investigated, no pharmacological approach has been established yet [5-8].  
ALI/ARDS is characterized by capillary leak and reduced fluid reabsorption, resulting in 
lung edema. The level of decreased rate of fluid clearance has significant prognostic value 
for morbidity and mortality [9]. In addition to reduced fluid reabsorption protein clearance 
is impaired as well. As shown in patients with ARDS non-survivors have three times 
higher alveolar protein concentrations than survivors [10,11].  
Several studies have tried to detect the underlying mechanism of impairment of alveolar 
fluid clearance in ALI/ARDS and various pathways have been suggested [12-14]. 
According to experimental evidence, the active sodium (Na+) transport is thereby the most 
important ion transport mechanism involved in fluid reabsorption out of the alveolar space 
[15,16]. The broadly accepted paradigm for Na+ transport in the alveoli is a two-step 
process: Na+ enters the cell by epithelial amiloride-sensitive Na+-channels (ENaC) located 
at the apical surface and is extruded by basolaterally located sodium-potassium-
adenosine-triphosphatase pumps (Na+/K+-ATPases) [17,18]. Research done in the last 
two decades has shown that this vectorial transport from apical to basal generates the 
osmotic force for water flow out of the alveolar air spaces [19-22]. This process can be up- 
or down regulated, implying an increased or diminished clearance of alveolar fluid. 
Studies have demonstrated that net vectorial fluid transport is reduced in human alveolar 
epithelial cells type II (AEC II) in ALI [23]. 
Patients suffering from ALI/ARDS most often need to be mechanically ventilated and 
therefore remain sedated in intensive care units (ICU) [24]. The overall effect of sedatives 
and anesthetics - volatile anesthetics included - on this disease is unclear. As previously 
demonstrated the inflammatory response upon endotoxin stimulation in AEC is partly 
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reversible in the presence of sevoflurane [25]. In an in vivo model of ALI oxygenation 
improved in the presence of sevoflurane [26]. However, at the same time, volatile 
anesthetics are suspected to impair sodium transport [27].  
Aim of this work was to investigate the effect of the nowadays commonly used volatile 
anesthetic sevoflurane on ENaC and Na+/K+-ATPase in vitro and in vivo. Based on our 
previous in vitro and in vivo results with a positive effect of sevoflurane [26] we 
hypothesized that in vitro activity of ENaC and Na+/K+-ATPase in endotoxin-injured AEC 
may be increased upon treatment with sevoflurane. Furthermore, we tried to clarify the 
impact of sevoflurane on edema in vivo in the endotoxin-induced lung injury model. We 
postulated that sevoflurane would improve alveolar fluid clearance. 
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Materials and methods 
1 In vitro assay 
Alveolar epithelial cells type II (AECII) 
The L2 cell line (CCL 149; American Type Culture Collection, Rockville, MD, USA) was 
derived trough cloning of adult female rat lung of AEC type II origin. Cells were cultured in 
Dulbecco’s modified Eagle’s Medium (DMEM, Invitrogen Corporation, Carlsbad, CA, 
USA), supplemented with 10% foetal bovine serum (FBS, Invitrogen Corporation, 
Carlsbad, CA, USA), 1% penicillin-streptomycin and 1% 4-(2-hydroxethyl)-1-
piperazineethanesulfonic acid buffer (HEPES, Invitrogen Corporation, Carlsbad, CA, 
USA). They were grown for 3 days in uncoated plates (Corning Inc., Croning, NY, USA) to 
> 95% confluence. 
 
Mixed alveolar epithelial cells (mAEC) 
Primary AEC were harvested following an established protocol [28, 29]. Briefly, lungs 
were explanted from male Wistar rats, injected with 10 ml of phosphate-buffered saline 
(PBS) containing 4U/ml porcine pancreas elastase (Sigma-Aldrich, Hamburg, Germany), 
and incubated for 20 minutes at 37°C. Trachea and large airways were discarded and 
lungs were minced. Elastase reaction was stopped with 5 ml FBS. After vigorous stirring 
for 20 minutes, cells were filtered and incubated for 1 hour at 37°C in petri dishes, 
previously coated with 1 mg/ml rat IgG (Sigma-Aldrich, Hamburg, Germany) in PBS, in 
order to remove immunocompetent cells. Unattached cells were washed away, and the 
remaining cells were cultured in DMEM/10%FBS. After an incubation time of 7 days a 
mixture of type I and type II cells (mAEC) were found (Figure 1). Type II character was 
detected analyzing sodium-dependent phosphate-cotransporter type IIb (NaPi IIb) [30,31], 
type I cells with detection of aquaporin 5 (AQP5) [32,33].  
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Stimulation with LPS and sevoflurane exposure 
DMEM/10% FBS of confluent AEC-monolayers was replaced by DMEM/1% FBS at least 
14 hours before starting the experiment. AEC were stimulated with lipopolysaccharide 
(LPS) from Escherichia coli, serotype 055:B5 (Sigma-Aldrich, Hamburg, Germany) in a 
concentration of 20 µg/ml in DMEM/1% FBS (control group with PBS) according to 
previous publications [34,35], and placed in two humidified, preheated (37°C) air-tight 
chambers (oxid anaerobic jar; Oxoid AG, Basel, Switzerland).  
AEC were exposed to 1 minimal alveolar concentration (MAC) = 2.2 vol. % sevoflurane 
(Sevorane®, Abbott AG, Baar, Switzerland) for 8 hours, representing a clinically relevant 
concentration of the volatile anesthetic as used in previously performed experiments [34]. 
A mixture of 5% CO2 and 95% air was directed trough a Sevotec 5 Vaporizer (Abbott, 
Switzerland), placed at the entrance of the chamber (for control only CO2 /air mixture). 
Within 5 min, sevoflurane reached the steady state concentration of 2.2 vol. % (monitored 
by Ohmedia 5330 Agent Monitor; Abbott AG). The chambers were sealed for 8 hours and 
incubated at 37°C. At the end of the experiment sevoflurane concentration was verified 
again to confirm the value of 2.2 vol%. 
 
22Na influx studies 
Measurement of 22Na flux trough amiloride-sensitive Na+ channels was performed as 
described [36]. Culture medium was removed, and cells on 6-well plates were rinsed twice 
and preincubated at 37°C for 20 min in a buffered sodium-free solution containing (in 
mM): 137 N-methylglucamine, 5.4 KCl, 1.2 MgSO4, 2.8 CaCl2 and 15 Hepes (pH 7.4). 
This solution was replaced by uptake solution composed of (in mM): 14 NaCl, 35 KCl, 96 
N-methylglucamine and 20 HEPES (pH 7.4) containing 0.5 µCi/ml of 22NaCl (37 MBq/mg 
Na) in absence or presence of 100 µM amiloride. Amiloride blocks sodium uptake via 
ENaC and was used as positive control for blocking sodium absorption. After an 
incubation time of 5 min cells were washed twice with 1 ml/well of an ice-cold solution 
containing (in mM): 120 N-methylglucamine and 20 HEPES (pH 7.4). Cells were 
Page 42 of 67 Clinical Experimental Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
7
solubilized in 0.3 ml/well trypsin for 3 min. Tracer activities were determined by liquid 
scintillation counting (Tri-carb 2900TR, liquid scintillation scanner, Packard, Chicago, IL, 
USA). 
  
86Rubidium influx studies 
The measurement of ouabain-sensitive rubidium (86Rb) influx was performed as 
previously described [37,38]. Assays were performed in a buffered solution A of the 
following composition (in mM): 120 NaCl, 5 RbCl, 1 MgSO4, 0.15 Na2HPO4, 0.2 NaH2PO4, 
4 NaHCO3, 1 CaCl2, 5 glucose, 2 lactate, 4 essential and nonessential amino acids, 20 
HEPES, and 0.1% bovine serum albumin (BSA). The osmotic pressure of solution A was 
adjusted by mannitol to 350 mosM, pH was 7.4. After removal of the culture medium half 
of the cells in 6-well plates were incubated with 1 ml/well of 4 mM ouabain at 37°C for 30 
minutes. Ouabain blocks Na+/K+-ATPase and was used as positive control for blocking the 
transporter. The other half was incubated with solution A. Subsequent plates were 
washed with 1 ml/well of solution A and incubated 5 min with 0.6 ml/well of Solution A 
supplemented with 1 µCi/ml 86RbCl (370 MBq/mg Rb). Uptake was stopped by washing 
the cells twice with 1 ml/well of ice-cold rinsing solution containing the following (in mM): 
140 N-methylglucamine, 1.2 MgCl2, 3 NaCl2, 10 Hepes, and 0.1% BSA at pH 7.4. 
Solubilized cells were traced by liquid scintillation counting. 
All chemicals were purchased from Sigma-Aldrich, Hamburg, Germany, culture media and 
their reagents from Invitrogen Corporation, Carlsbad, CA, USA. Radioactive tracers were 
supplied by PerkinElmer AG, Schwerzenbach, Switzerland.  
 
Statistical analysis 
Each experimental setup was performed three times, each conducted in sextuplets. Data 
of the three experiments were taken together and analysed (n=18). Values are expressed 
as mean +/- SD. Optical analysis of boxplots suggested normal distribution of data. 
Confirmation was done by a Shapiro Wilk Test. The effects of sevoflurane were compared 
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with the control group (PBS group) for K+ - and Na+ -influx and tested by analysis of 
variances for repeated measurements (one-way ANOVA), including a Tukey-Kramer 
Multiple comparison Test. Graphpad Prism4® Graphpad Instat3® (GraphPad software, La 
Jolla, CA, USA) was used for statistical analyses. P-values <0.05 are considered 
statistically significant. 
 
2 In vivo assay 
Animal preparation  
After approval from the local animal care and use committee (Zürich, Switzerland) 
experiments were performed with pathogen-free, male Wistar rats (Charles River, 
Sulzfeld, Germany), (body weight 350 -500 g). The rats were kept in standard cages at 22 
°C (12 hours light /12 hour dark). Food and water were supplied ad libitum.  
Induction of anesthesia and monitoring was performed as previously described [26]. Rats 
were tracheotomized. After insertion of a sterile metal cannula, animals were ventilated in 
parallel (Servo Ventilator 300, Maquet, Solna, Sweden). Pressure controlled ventilation 
was set with 30 breathes per minute, pressure was 3/14 cm H2O, inspiration to expiration-
ratio 1:2, and fractional inspired oxygen concentration (FiO2) was 100%. Arterial blood 
was analysed at 0, 2, 4, 6 and 8 hours. Using 100% FiO2 during the whole experiment, the 
oxygen capability of the lung is represented by the oxygen tension (PaO2 in mmHg) in 
arterial blood gas samples (oxygenation index: PaO2/FiO2). Body temperature was 
controlled by rectal temperature measurement and corrected to 37°C by a heating lamp. 
 
Experimental design  
Rats were randomized into three different groups, using sealed envelopes: a) 
propofol/PBS; b) propofol/LPS and c) sevoflurane/LPS (n=6 in all groups). Rats were 
intratracheally instilled with 150 µg LPS in 300 µl PBS (control with PBS only) [39], 
immediately followed by randomisation in either propofol or sevoflurane group (co-
conditioning). Anesthesia was performed as described [26]. 
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RNA extraction and real-time PCR for α-ENaC, γ-ENaC and α1-Na+/K+-ATPase 
Eight hours after the onset of injury rats were euthanized and lungs were explanted, 
shock-frozen in liquid nitrogen and stored at -80°C for isolation of mRNA. 
Total RNA was isolated form lung tissue using the RNeasy® Mini Kit (Qiagen, Basel, 
Switzerland) according to the manufacture’s protocol. RNA amounts were determined by 
absorbance at 260 nm. 
Reverse transcription and real-time quantitative TaqMan™ polymerase chain reaction 
(PCR) were performed as described [26]. Specific primers (Microsynth, Balgach, 
Switzerland) and labeled TaqMan probes (Roche Applied Science, Switzerland) were 
designed for α- and γ- subunits of ENaC, for α1-subunit of Na+/K+-ATPase and 18S as 
housekeeping gene. All primers and probes used in the experiments are presented in 
Tab. 1. Each experimental PCR run was performed in duplicate with simultaneous 
negative controls without template. 
For quantitation of gene expression the comparative Ct method was used as described by 
Livak et al. [40]. The Ct values of samples (propofol/LPS and sevoflurane/LPS) and 
control (propofol/PBS) were normalized to the housekeeping gene (18S) and calculated 
as follows: 2-[delta] [delta] Ct, where [delta][delta]Ct = [delta]Ct, samples  - [delta]Ct, controls. 
 
Lung wet/dry ratio 
Sevoflurane/LPS animals were given 150 µg LPS in 300 µl PBS with or without 100 µM 
amiloride to block sodium resorption via ENaC [41] (Sigma-Aldrich, Hamburg, Germany). 
After 8 hours animals were sacrificed, lungs were explanted, and wet weight was 
measured. Thereafter, lungs were air dried for 72 hours at 65°C and lung dry weight was 
quantified. Wet/dry ratio (w/d) was calculated as follows [42]: w/d = weightwet / weightdry  
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Statistics 
Values are expressed as mean ± SD, n=6 per group. Optical analysis of boxplots 
suggested normal distribution of data. Confirmation was done by a Shapiro Wilk test. Vital 
parameters were tested by analysis of variances for repeated measurements (one-way 
ANOVA) with a Tukey-Kramer Multiple post-hoc test. Real-time PCR and wet/dry-ratio 
data were tested using student’s T-test. Graphpad Prism4® and Graphpad Instat3® 
(GraphPad software, La Jolla, CA, USA) were used for statistical analyses. P-values less 
or equal to 0.05 are considered statistically significant. 
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Results 
Cell survival 
As described in previous experiments [34,25], cell survival was not influenced upon 
sevoflurane and LPS exposure. This was confirmed with a cytotoxic assay (determination 
of lactate dehydrogenase, LDH, Promega, Madison, WI, USA, data not shown).  
 
Cell characteristics of mAEC 
As seen in Figure 1, primary culture of mAEC represented both type I and II AEC, 
detected by real-time PCR (Tab. 1). 
 
Co-exposure of AECII to LPS and sevoflurane: Effects on sodium transport via 
ENaC and Na+/K+-ATPase: 
ENaC activity was assessed in AECII monolayer measuring 22sodium (22Na) influx. As 
shown in Figure 2A, stimulation with LPS impaired 22Na-influx by 17.4% ± 13.3% SD 
(p<0.05) compared to control group. In the presence of sevoflurane, sodium influx into 
AECII improved in the LPS group, reaching control values (p<0.05). 
Activity of Na+/K+-ATPase, measured by 86rubidium (86Rb) influx, revealed a 16.2% ± 
13.1% (p<0.01) decrease of 86Rb-influx upon LPS stimulation (Figure 2B). In LPS-
stimulated AECII co-exposed to sevoflurane 86Rb-influx reached values comparable to the 
control group (p<0.01). 
 
Co-exposure of mAEC to LPS and sevoflurane: Effects on sodium transport via 
ENaC and Na+/K+-ATPase: 
No difference in 22Na-influx was observed in all four groups (Figure 3A).   
mAEC showed an increased Na+/K+-ATPase activity of 23.7% ± 24.5% in the LPS group, 
26.1% ± 38.6% in the sevo/LPS group (both p<0.05). Sevoflurane did not have a 
significant impact on LPS-injured mAEC (Figure 3B).  
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In vivo effect of co-stimulation with LPS and sevoflurane on ENaC and Na+/K+-
ATPase mRNA expression 
mRNA of α-ENaC was decreased by 58% ± 26.9% in the propofol/LPS compared to 
propofol/PBS group (p<0.05) (Figure 4A). Sevoflurane co-conditioning did not impact on 
expression of α-ENaC mRNA. γ-ENaC mRNA was downregulated in both LPS groups 
compared to propofol/PBS: it decreased by 81.7% ± 12.9% (p<0.01) in the propofol/LPS 
and 71.7% ± 17.3% (p<0.01) in the sevoflurane/LPS group (Figure 4B) with no intergroup 
difference. 
Despite an increased expression of α1-Na+/K+-ATPase mRNA in LPS-treated compared to 
control animals (increase of 46.5% ± 114.6 in the propofol/LPS, and 99.4% ± 81.4 in the 
propofol/LPS group), values between all groups did not differ significantly (Figure 4C). 
 
In vivo effect of co-stimulation with LPS and sevoflurane: Oxygenation index 
(pO2/FiO2) 
While LPS application impaired oxygenation in the propofol group, oxygenation could be 
maintained in sevoflurane/LPS-treated animals comparable to propofol/PBS (Figure 5): At 
6 hours, propofol/LPS animals presented with an oxygenation index of 298 mmHg 
compared to 6 hours sevoflurane/LPS animals with 474 mmHg (p<0.05). At 8 hours the 
difference even increased with 198 mmHg in propofol/LPS animals to 454 mmHg in LPS 
animals with sevoflurane application (p< 0.001). 
 
Wet/dry ratio of differently treated animals 
A 27.7% ± 21.2% higher wet/dry ratio in animals treated with propofol/LPS compared to 
sevoflurane/LPS was observed (p<0.05) (Figure 6A). Sevo/LPS animals treated with 
amiloride showed similar wet/dry-ratios as the group without amiloride application (Figure 
6B).  
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Discussion 
With the current data two main results can be summarized: First, sevoflurane has a 
stimulating effect on the pump function of sodium channels in LPS-injured AECII in vitro. 
However, no such impact was observed in a mixed culture of type I and II AEC (mAEC), 
this cell composition rather reflecting an in vivo situation with predominantly type I cells in 
the lung. In vivo data underline these findings showing that the presence of sevoflurane 
does not influence edema resolution. Secondly, sevoflurane has a positive impact on the 
course of LPS-induced injury in vivo. Animals anesthetized with sevoflurane presented 
with a better oxygenation. 
Transepithelial sodium transport plays an important role in fluid clearance in normal and 
injured alveoli. α-ENaC thereby seems to be crucial as α-ENaC-deficient mice died shortly 
after birth due to lung edema ven without pulmonary inflammation [43]. In addition, 
previous in vivo experiments have demonstrated that blocking of epithelial sodium 
channels in a rat model of hyperoxia-induced lung injury significantly increased 
extravascular lung fluid volume [44]. In the situation of ALI alveolar fluid transport can be 
up- or downregulated [45]. Hypoxia inhibits transepithelial sodium transport in ex vivo 
lungs [16], while endotoxin A from Pseudomonas aeruginosa stimulates alveolar fluid 
clearance in rats [46], probably by cytokines-induced stimulation of sodium uptake. On the 
contrary, intratracheal application of endotoxin impaired alveolar fluid clearance in adult 
rats at 6 hours of injury [26,47]. Evidence from previous studies indicate that a complex 
network of inflammatory cytokines and chemokines mediate and modify the inflammatory 
process in lung injury including edema formation [48-50]. 
It is known that inflammation in AEC is mitigated by application of sevoflurane [25]. Our in 
vitro investigations in AECII showed that LPS-induced impairment of both, ENaC and 
Na+/K+-ATPase is reversed upon co-exposure to sevoflurane. These data suggest that 
active sodium transport and thus water transport can functionally be increased in injured 
AECII by administration of sevoflurane. So far only type II cells were considered as the 
important regulators for salt and water transport [51]. However, since both type I and II 
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cells AEC express sodium transport channels [52,53] also AECI might play an important 
role in water and salt homeostasis in the lung [52]. Therefore, after the positive findings in 
AECII, in vitro experiments regarding sodium transport were re-assessed in a mixture of 
type I and II cells, a setup, which more likely reflects the in vivo situation with only 5% of 
type II and 95% type I cells in the lungs. With this mixture of AEC (mAEC) no LPS-
induced change or a significant influence of sevoflurane was observed for functionality of 
ENaC. For Na+/K+-ATPase we could show increased activity upon LPS exposure, while 
sevoflurane did not have any significant impact on its function. Therefore we conclude that 
AECI are not actively involved in water reabsorption with regard to sodium channels. 
A previous study showed that oxygenation significantly improved using sevoflurane in a 
post-conditioning setup in a LPS-induced ALI model (intratracheally applied LPS, followed 
2 hours later by application of sevoflurane compared to propofol anesthesia) [26]. The 
present promising in vitro results from AECII encouraged us to elucidate the question to 
what extent sevoflurane may influence either edema resolution or edema formation. We 
were able to show that wet/dry ratio in the sevoflurane-treated animals was significantly 
lower compared to the propofol/LPS group, linking better oxygenation to less alveolar 
edema. However, when blocking the activity of ENaC using amiloride, wet/dry ratio 
remained unchanged. This important result suggests that sevoflurane most likely does not 
improve alveolar fluid reabsorption, but rather acts on the inflammatory side inhibiting the 
production of inflammatory mediators, which in consequence decreases vascular 
permeability. If alveolar water absorption had been more important than edema formation 
one would have expected a clearly increased wet/dry-ratio in case of blocked ENaC [41].  
Another interesting observation of the current in vivo experiments is the fact that co-
conditioning with sevoflurane is more effective in amelioration of oxygenation than 
postconditioning with the volatile anesthetic [26]. This finding suggests that an early 
treatment with sevoflurane could inhibit the increase of permeability and attenuate injury-
induced vascular leakage.    
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The present study has several limitations that need to be addressed. Discussion from in 
vitro experiments is limited as the interaction with cells of different character is missing. 
Another concern lies in the experimental setup of ALI used. Even if intratracheal 
application of LPS is defined as a relevant in vitro and in vivo animal model for lung injury, 
it does not fully represent ALI in patients. Therefore, conclusions cannot necessarily be 
translated to a clinical situation. Furthermore, due to the fact that lungs could not be 
utilized for both measurement of lung wet/dry ratios and lung RNA-analysis experiments 
had to be repeated using different animals. This of course may create a sample bias, 
which we tried to minimize by following our strict experimental protocols. Nevertheless, 
despite these limitations the present study provides new information regarding the 
protective effect of volatile anesthetics in ALI. 
In conclusion, these data reveal that sevoflurane reverses the inhibitory effect of LPS on 
the function of ENaC and Na+/K+-ATPase in AECII in vitro. Sevoflurane exposure can 
positively influence the course of LPS-induced lung injury with regard to oxygenation. This 
effect, however, seems not to be mediated by increased fluid clearance, but rather by the 
anti-inflammatory properties of sevoflurane leading to less edema formation. 
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Figure legend 
 
Figure 1:  
TaqMan real-time PCR of AECII and mAEC. Detection of type I and type II characteristic 
ion transporters. Values are mean ± standard deviation. N=6 per group. 
 
Figure 2A:  
22Na-uptake via epithelial sodium channel ENaC, relative counts per minute in the 
different groups. AECII cells were incubated for 8 hours with or without lipopolysaccharide 
(LPS) and with or without sevoflurane (Sevo). Values are mean ± standard deviation. 
N=18 per group.  
* p<0.05 vs other 3 groups 
 
Figure 2B:  
Na+/K+-ATPase activity measured by 86rubidium uptake in alveolar epithelial type II cells 
(AECII), relative counts per minute.  Cells were incubated for 8 hours with or without 
lipopolysaccharide (LPS) and with or without sevoflurane (Sevo). Values are mean ± 
standard deviation. N=18 per group.  
** p<0.01 vs other 3 groups 
 
Figure 3A:  
22Na-uptake via epithelial sodium channel ENaC, relative counts per minute in the 
different groups. A mixture of type I and II alveolar epithelial cells (mAEC) cells were 
incubated for 8 hours with or without lipopolysaccharids (LPS) and with or without 
sevoflurane (Sevo). Values are mean ± standard deviation. N=18 per group. 
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Figure 3B:  
Na+/K+-ATPase activity measured by 86rubidium uptake in mAEC, relative counts per 
minute. mAEC were incubated for 8 hours with or without lipopolysaccharide (LPS) and 
with or without sevoflurane (Sevo). Values are mean ± standard deviation. N=18 per 
group. 
* p<0.05 vs control  
 
Figure 4A: 
Expression of the α-subunit of epithelial sodium channel (α-ENaC) mRNA in differently 
treated animals. Propofol/phosphate-buffered saline (PBS) served as control. LPS = 
lipopolysaccharide. Values are mean ± standard deviation. N=6 per group. 
* p<0.05 vs other 2 groups 
 
Figure 4B: 
Expression of the γ-subunit of epithelial sodium channel (γ-ENaC) mRNA in differently 
treated animals. Propofol/phosphate-buffered saline (PBS) served as control. LPS = 
lipopolysaccharide. Values are mean ± standard deviation. N=6 per group. 
** p<0.01 vs propofol/PBS  
 
Figure 4C: 
Expression of α1-subunit of Na+/K+-ATPase mRNA in differently treated animals. 
Propofol/phosphate-buffered saline (PBS) served as control. LPS = lipopolysaccharide. 
Values are mean ± standard deviation. N=6 per group. 
 
Figure 5: 
Arterial oxygen partial pressure in mmHg of blood gas analysis in differently treated 
animals. Propofol/phosphate-buffered saline (PBS) served as control. LPS = 
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lipopolysaccharide. Blood gas measurements were taken at the time points 0, 2, 4, 6 and 
8 hours.. Values are mean ± standard deviation. N=6 per group. 
# p<0.05 vs time points 0, 2 and 4 hours 
* p<0.05 vs time point 6 hours 
 
Figure 6A:  
Wet/dry ratio of rat lungs treated with lipopolysaccharide (LPS) and either sevoflurane or 
propofol for 8 hours. Values are mean ± standard deviation. N=6 per group. 
* p<0.05 
 
Figure 6B: 
Wet/dry ratio of rat lungs. Animals were treated with lipopolysaccharide (LPS) and 
sevoflurane for 8 hours. Half of the animals received amiloride intratracheally in order to 
block ENaC. Values are mean ± standard deviation. N=6 per group.  
 
Table 1:  
Primer sequences and probes used for TaqMan Real-time PCR 
α-ENaC: alpha-subunit of the epithelial sodium channel, γ-ENaC: gamma-subunit of the 
epithelial sodium channel, α1-Na+/K+-ATPase: sodium-potassium triphosphatasen (α1-
subunit), AQP5: Aquaporin 5, NaPi IIb: Sodium dependent phosphate cotransporter type 
IIb, 18S: housekeeping gene (ribosomal origin). 
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Tables 
 
Table 1 
 
Gene Primer sequence and corresponding probe Fragment size 
α-ENaC forward: 5’ tgt gac tac cga aag cag agc 3’ 
reverse: 5’ agg ctt ccg aca ctt gga g 3’ 
probe #26 
102bp 
γ-ENaC forward: 5’ agc aac acc cca act gga t 3’ 
reverse: 5’ agg att gct gca cac tga tt 3’ 
probe #26 
93bp 
α1-Na+/K+-ATPase  forward: 5’ act tgg gca ctg aca tgg tt 3’ 
reverse: 5’ cac aag ttt gtc cgt ttt gg 3’ 
probe #26 
104bp 
NaPi IIb forward: 5’ ccc agg aag agg agc aaa a 3’ 
reverse: 5’ tca gga gct ttg tgc caa c 3’ 
probe #64 
72bp 
Aquaporin 5 forward: 5’ gct ccg agc tgt ctt cta cg 3’ 
reverse: 5’ gcg ttg tgt tgt tgt tca gc 3’ 
probe #20 
131bp 
18S forward: 5’ gga gag gga gcc tga gaa ac 3’ 
reverse: 5’ tcg gga gtg ggt aat ttg c 3’ 
probe #74   
70bp 
probe #20 5’ ctg gct gg 3’ 
 
probe #26 5’ cag ccc ag 3’ 
 
probe #64 5’ cca ggc tg 3’ 
 
probe #74   5’ ggc agc ag 3’ 
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